Perform Another (Advanced) Search

1.  Study Posting (1955) Trial #163221, Atrial Fibrillation, Haverhill, MA
...Trial #163221, Atrial Fibrillation, Haverhill, MA Trial Information Do you have ATRIAL FIBRILLATION and planned ANTICOAGULANT THERAPY? This is a study for subjects with ATRIAL FIBRILLATION whom have anticoagulant therapy planned for the course of this study. This study may continue up to 3 ...
View Page

2.  Newly Approved Drug Therapies (659) Angiomax (bivalirudin), The Medicines Company,
...Angiomax (bivalirudin) Company: The Medicines Company Approval Status: Approved December 2000 Treatment Area: As an anticoagulant in conjunction with aspirin General Information Angiomax (bivalirudin) is indicated as a thrombin-specific anticoagulant to be used in conjunction with aspirin in patients with unstable angina undergoing percutaneous transluminal ...
View Page

3.  Study Posting (4519) Trial #123204, Cardiovascular Abnormalities, Basel, Switzerland
...rate, in patients with mechanical heart valve replacement. Patients will be randomized to low dose anticoagulant plus self-management, very low dose anticoagulant with patient self-testing and telemetry once weekly, or very low dose anticoagulant with patient ...
View Page

4.  Study Posting (4519) Trial #123115, Cardiovascular Abnormalities, Rome, Italy
...rate, in patients with mechanical heart valve replacement. Patients will be randomized to low dose anticoagulant plus self-management, very low dose anticoagulant with patient self-testing and telemetry once weekly, or very low dose anticoagulant with patient ...
View Page

5.  Study Posting (4519) Trial #123775, Cardiovascular Abnormalities, Oldenburg, Germany
...rate, in patients with mechanical heart valve replacement. Patients will be randomized to low dose anticoagulant plus self-management, very low dose anticoagulant with patient self-testing and telemetry once weekly, or very low dose anticoagulant with patient ...
View Page

6.  Study Posting (4519) Trial #123289, Cardiovascular Abnormalities, Magdeburg, Germany
...rate, in patients with mechanical heart valve replacement. Patients will be randomized to low dose anticoagulant plus self-management, very low dose anticoagulant with patient self-testing and telemetry once weekly, or very low dose anticoagulant with patient ...
View Page

7.  Study Posting (4519) Trial #123768, Cardiovascular Abnormalities, Ludwigshafen, Germany
...rate, in patients with mechanical heart valve replacement. Patients will be randomized to low dose anticoagulant plus self-management, very low dose anticoagulant with patient self-testing and telemetry once weekly, or very low dose anticoagulant with patient ...
View Page

8.  Study Posting (4519) Trial #124878, Cardiovascular Abnormalities, Lahr, Germany
...rate, in patients with mechanical heart valve replacement. Patients will be randomized to low dose anticoagulant plus self-management, very low dose anticoagulant with patient self-testing and telemetry once weekly, or very low dose anticoagulant with patient ...
View Page

9.  Study Posting (4519) Trial #124669, Cardiovascular Abnormalities, Kassel, Germany
...rate, in patients with mechanical heart valve replacement. Patients will be randomized to low dose anticoagulant plus self-management, very low dose anticoagulant with patient self-testing and telemetry once weekly, or very low dose anticoagulant with patient ...
View Page

10.  Study Posting (4519) Trial #126127, Cardiovascular Abnormalities, Bad Oeynhausen, Germany
...rate, in patients with mechanical heart valve replacement. Patients will be randomized to low dose anticoagulant plus self-management, very low dose anticoagulant with patient self-testing and telemetry once weekly, or very low dose anticoagulant with patient ...
View Page

11.  Study Posting (4519) Trial #124745, Cardiovascular Abnormalities, Vienna, Austria
...rate, in patients with mechanical heart valve replacement. Patients will be randomized to low dose anticoagulant plus self-management, very low dose anticoagulant with patient self-testing and telemetry once weekly, or very low dose anticoagulant with patient ...
View Page

12.  CenterWatch: New Medical Therapies in Disease Category (385), Blood Clots
...issued positive results from a phase Ib trial of NU172 as a potential short-acting anticoagulant during medical procedures. This single center study enrolled 24 healthy male subjects who were placed ...
...January 5, 2004 AstraZeneca reported results of its phase III, EXULT B trial comparing the anticoagulant, Exanta (ximelagatran) , to warfarin for the prevention of venous thormboembolism (VTE) in subjects undergoing total ...
View Page

13.  Study Posting (1570) Trial #156483, Atrial Fibrillation, Morristown, NJ
...The objective of this study is to evaluate wether the new investigational, neutralizable blood thinner (anticoagulant) "biotinylated idraparinux", administered once weekly under the skin, is at least as efficient to prevent ...
...brain and in the other organs than the standard of care with warfarin an oral anticoagulant whose doses are adjusted according to a regular monitoring of a blood coagulation test (INR ...
View Page

14.  Newly Approved Drug Therapies (247) Warfarin Sodium tablets, Barr Laboratories,
...Drug Name: Warfarin Sodium tablets Company: Barr Laboratories Approval Status: Approved March 1997 Treatment Area: Anticoagulant, or "blood thinner" to keep blood clots from forming or getting larger General Information Seven ...
View Page

15.  Newly Approved Drug Therapies (624) Argatroban Injection, Texas Biotechnology Corporation, SmithKline Beecham,
...Area: Heparin-induced thrombocytopenia and thrombosis syndrome General Information Heparin is the most commonly used anticoagulant for patients requiring immediate anticoagulation therapy. Heparin-induced thrombocytopenia (HIT) has an immunologic basis and ...
...It does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or induced reactions, including fibrin formation; activation of coagulation factors ...
View Page

16.  CenterWatch: List of Newly Approved Drug Thearapies
...percutaneous transluminal coronary angioplasty (PTCA), Approved December 2000 Argatroban Injection ; Texas Biotechnology Corporation, SmithKline Beecham; Anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia., Approved June 2000 ...
...of age and older, Approved September 2000 Hematology Argatroban Injection ; Texas Biotechnology Corporation, SmithKline Beecham; Anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia., Approved June 2000 ...
View Page

17.  Study Posting (713) Trial #150276, Blood Clots, Charlottesville, VA
...or pulmonary embolism) in the past 12 months and are currently taking blood thinner medications (anticoagulants) for a for research study. This purpose of this study is to determine the risks ...
View Page

18.  Newly Approved Drug Therapies (422) Refludan, Hoechst Marion Roussel,
...II). HIT type II is a rare, allergy-like adverse reaction to heparin, a standard anticoagulant therapy. HIT type II is characterized by a rapid and serious decline in the blood ...
View Page

19.  Study Posting (713) Trial #159752, Thrombosis, Charlottesville, VA
...patients with DVT with acceptable safety and cost. The most common treatment for DVT uses anticoagulant drugs (blood thinners), such as heparin and warfarin, to stop the clot from growing within ...
View Page

20.  Study Posting (3103) Trial #144751, Osteoarthritis, Tucson, AZ
...active GD ulceration <90 days prior to screening • Patients taking or anticipated to require lithium, anticoagulants or any antiplatelet therapy during the course of the study Cedar, MA, CRC Quality of ...
View Page